JESSIE CORREA: Open Payments
NPI 1093202889 · BESSEMER, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$741 in 37 payments from 12 companies in 2025. Trend: 2023 $1,821 · 2024 $3,011 · 2025 $741
Food & beverage: $741
| Company | Payments | Amount |
|---|---|---|
| Celltrion USA Inc. | 6 | $115 |
| QOL Medical, LLC | 4 | $112 |
| ABBVIE INC. | 6 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $99 |
| Phathom Pharmaceuticals, Inc. | 3 | $51 |
| Gilead Sciences, Inc. | 2 | $48 |
| Janssen Biotech, Inc. | 2 | $44 |
| Madrigal Pharmaceuticals | 1 | $40 |
| Novo Nordisk Inc | 2 | $38 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $37 |
Products named: VEGZELMA, Sucraid, ENTYVIO, RINVOQ, VOQUEZNA, TREMFYA, REZDIFFRA, Wegovy.
Industry payments across AL — which companies pay providers there.
